Ysios, Omega lead €15m series-A for Anaconda Biomed

Spanish venture capital firm Ysios and its Boston-based peer Omega led the round alongside Banco Sabadell as new investors in the business. Existing investor Innogest Capital also took part in the round and deployed a €3.4m equity ticket via its Innogest Capital II fund.

Following the deal, Ysios general partner Josep Sanfeliu and Omega managing director Claudio Nessi will join Anaconda's board of directors, while Innogest's Giovanni Leo will continue representing the Italian GP on the board, according to a statement.

The company aims to use the capital injection to enter the clinical stage with its ANCD Brain device and receive approvals from the European and US authorities.

Previous funding
Innogest led a seed funding round for the business in May 2016 alongside several local business angels.

Company
Headquartered in Barcelona, Anaconda develops a medical device called ANCD Brain, which aims to aid in performing mechanical thrombectomies targeting acute ischemic strokes. The pre-revenues business was founded in 2015 and currently employs five people.

People
Ysios Capital – Josep L Sanfeliu (general partner).
Omega Funds – Claudio Nessi (managing director).
Innogest Capital – Claudio Rumazza (partner).
Anaconda Biomed – Ofir Arad (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Healthcare
• Southern Europe
• Venture
• Spain
• Ysios Capital